JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Search

Stevanato Group SpA

Geschlossen

BrancheGesundheitswesen

15.69 1.42

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

15

Max

15.78

Schlüsselkennzahlen

By Trading Economics

Einkommen

10M

49M

Verkäufe

23M

303M

KGV

Branchendurchschnitt

28.8

90.422

EPS

0.162

Dividendenrendite

0.31

Gewinnspanne

16.205

Angestellte

5,521

EBITDA

10M

73M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+73.3% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.31%

2.13%

Nächstes Ergebnis

5. März 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2B

4.7B

Vorheriger Eröffnungskurs

14.27

Vorheriger Schlusskurs

15.69

Nachrichtenstimmung

By Acuity

50%

50%

147 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Stevanato Group SpA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Feb. 2026, 23:52 UTC

Akquisitionen, Fusionen, Übernahmen

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2. Feb. 2026, 23:52 UTC

Akquisitionen, Fusionen, Übernahmen

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2. Feb. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2. Feb. 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2. Feb. 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2. Feb. 2026, 23:23 UTC

Ergebnisse

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2. Feb. 2026, 22:57 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2. Feb. 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2. Feb. 2026, 21:51 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. Feb. 2026, 21:49 UTC

Ergebnisse

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2. Feb. 2026, 21:39 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:36 UTC

Ergebnisse

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2. Feb. 2026, 21:34 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2. Feb. 2026, 21:23 UTC

Ergebnisse

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2. Feb. 2026, 21:19 UTC

Ergebnisse

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2. Feb. 2026, 21:17 UTC

Ergebnisse

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2. Feb. 2026, 21:17 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:10 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:08 UTC

Ergebnisse

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2. Feb. 2026, 21:07 UTC

Ergebnisse

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q Net $608.7M >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q Rev $1.41B >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q Adj EPS 25c >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q EPS 24c >PLTR

2. Feb. 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Peer-Vergleich

Kursveränderung

Stevanato Group SpA Prognose

Kursziel

By TipRanks

73.3% Vorteil

12-Monats-Prognose

Durchschnitt 27 USD  73.3%

Hoch 30 USD

Tief 24 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Stevanato Group SpA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

2

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

21.56 / 22.61Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

147 / 352 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Stevanato Group SpA

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
help-icon Live chat